


# vivo ISAR

Polymer-Free Sirolimus Eluting Stent

World's 1st Dual Drug Polymer free Stent



## Dual Drug DES

- Using Probucol as an alternative to polymer for stent coating matrix. Due to its high lipophilicity, it facilitates retardation of Sirolimus release in a manner similar to that achieved by polymer coating
- Sirolimus is a potent Immunosuppressant drug with established clinical data.

## Microporous Surface

- Stent surface has micro-pores which act like reservoirs for delivering the drug to the targeted site.

## Abluminal Coating

- Dual drug matrix coated only on the abluminal side using patented stent technology for drug release only to target tissue
- Abluminal coating ensures better endothelialisation and reduces the incidence of stent thrombosis

## Shellac Resin

- Shellac resin helps for the smooth top coat of the stent and prevents dual-drug matrix break ups during stent expansion

# vivo ISAR

Polymer-Free Sirolimus Eluting Stent

## Ordering Information

Length Ø [mm]	VIVO ISAR Reference No.						
	Diameter (mm)						
	2.00 mm	2.25 mm	2.50 mm	2.75 mm	3.00 mm	3.50 mm	4.00 mm
8.00	VISR2008	VISR2208	VISR2508	VISR2708	VISR3008	VISR3508	VISR4008
12.00	VISR2012	VISR2212	VISR2512	VISR2712	VISR3012	VISR3512	VISR4012
16.00	VISR2016	VISR2216	VISR2516	VISR2716	VISR3016	VISR3516	VISR4016
18.00	VISR2018	VISR2218	VISR2518	VISR2718	VISR3018	VISR3518	VISR4018
21.00	VISR2021	VISR2221	VISR2521	VISR2721	VISR3021	VISR3521	VISR4021
24.00	VISR2024	VISR2224	VISR2524	VISR2724	VISR3024	VISR3524	VISR4024
28.00	VISR2028	VISR2228	VISR2528	VISR2728	VISR3028	VISR3528	VISR4028
32.00	VISR2032	VISR2232	VISR2532	VISR2732	VISR3032	VISR3532	VISR4032
36.00				VISR2736	VISR3036	VISR3536	VISR4036
40.00				VISR2740	VISR3040	VISR3540	VISR4040
44.00				VISR2744	VISR3044	VISR3544	VISR4044
48.00				VISR2748	VISR3048	VISR3548	VISR4048

\* Please contact our Customer Care for available sizes

## COMPLIANCE CHART

Balloon Ø [mm]	Inflation Pressure (atm)														
						NP					RBP				
	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
Ø 2.00	1.83	1.87	1.90	1.93	1.96	2.00	2.03	2.06	2.10	2.13	2.16	2.20	2.23	2.26	2.29
Ø 2.25	2.08	2.11	2.14	2.18	2.21	2.25	2.28	2.31	2.35	2.38	2.42	2.45	2.48	2.52	2.55
Ø 2.50	2.33	2.36	2.40	2.43	2.47	2.50	2.53	2.57	2.60	2.64	2.67	2.70	2.74	2.77	2.81
Ø 2.75	2.58	2.61	2.65	2.68	2.71	2.75	2.78	2.81	2.85	2.88	2.91	2.94	2.98	3.01	3.04
Ø 3.00	2.81	2.85	2.89	2.92	2.96	3.00	3.04	3.07	3.11	3.15	3.18	3.22	3.26	3.29	3.33
Ø 3.50	3.29	3.34	3.38	3.42	3.46	3.50	3.55	3.59	3.63	3.67	3.71	3.76	3.80	3.84	3.88
Ø 4.00	3.75	3.80	3.85	3.90	3.95	4.00	4.06	4.11	4.16	4.21	4.26	4.31	4.36	4.41	4.46

Manufactured By:  
**Translumina Therapeutics LLP**  
Plot No. 12, Pharmacy, Selaqui, Dehradun 248 197 (Uttarakhand) India  
Manufacturing Licence No. MFG/MD/2019/000227

Registered Office:  
**Translumina Therapeutics LLP**  
Ground Floor, Metro Tower, LSC MOR Land, New Rajinder Nagar, New Delhi 110 060 - India

Under Technological Collaboration With:  
**Artic GmbH**  
Birkenweg 25,  
75015 Bretten, Germany

**CMC Medical Devices & Drugs S.L.**  
c/HoracioLengo Nº 18, CP 29006, Malaga - Spain  
Tel: +34951214054 Fax: +34952330100  
Email: mmateos@cmcmedicaldevices.com  
www.cmcmedicaldevices.com

Customer Care No.: 011-28742874  
Email: info@translumina.in  
Visit www.translumina.in for more details.

**VIVO ISAR** is a registered trademark of Translumina Therapeutics LLP

Please refer to the **Instructions for Use** supplied with these devices for indications, contraindications, adverse effects, suggested procedures, warnings and precautions.

# vivo ISAR

POLYMER-FREE SIROLIMUS ELUTING CORONARY STENT SYSTEM



Sustaining life  
in more ways than one.

**2004** **CATHETERIZATION  
CARDIOVASCULAR INTERVENTIONS**  
89:367-374 (2017)

At 2 years, microporous surface was found to be equally safe as compared to electropolished surface

**2010** **JACC**

At 2 years, VIVO ISAR demonstrated 43% reduction in binary restenosis in comparison to endeavour sprint and 23% reduction in

**2016** **CARDIOVASCULAR  
DIABETOLOGY**

At 5 years, outcomes of patients treated with VIVO ISAR compared with durable polymer based ZES were similar in sub group of diabetes.

**2019 ISAR TEST 5**

In this long-term analysis at 10 years, Polymer free VIVO ISAR showed similar efficacy and safety profile as resolute integrity



**2008** **Biomaterials**

In pre-clinical study, VIVO ISAR demonstrated ideal Drug Release Kinetics & better endothelialisation as compared to polymer based and conventional polymer free stent

**2016** **JACC**

At 5 years, VIVO ISAR with no polymer demonstrates similar rates of definite or probable stents thrombosis as PP-ZES

**2017** **SCAI** society of cardiovascular  
Angiography & Interventions

At 5 years, outcome of patients treated with VIVO ISAR compared with durable based ZES were similar in sub group of STEMI.